Compare EOG Resources Inc (EOG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs BIO-TECHNE Corp — how do they compare? EOG Resources Inc trades at $148.16 (market cap $77.90B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: EOG Resources Inc is far larger — about 6.9× BIO-TECHNE Corp's market cap, and EOG Resources Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and BIO-TECHNE Corp for 64 Days on average.
| EOG | TECH | |
|---|---|---|
Market Cap | $77.90B | $11.36B |
Volume | 2,930,386 | 5,390,331 |
Sector | Energy | Health |
52-Week High | $153.74 | $72.61 |
52-Week Low | $101.78 | $43.31 |
Typical Hold Time | 59 Days | 64 Days |
Enterprise Value | $81.24B | $11.39B |
Dividend Yield | 2.75% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $148.51, up 2.98% today, with a bullish technical signal from moving averages and strong analyst support. The company demonstrates robust profitability with a 25.81% net income margin and 22.51% ROE, though revenue declined to $22.58B in 2025. Recent earnings beats and a consensus price target of $164.77 highlight positive momentum, while cash flow trends show significant investing outflows for growth.
The outlook for EOG is favorable given its low P/E of 11.56, consistent dividend payments, and projected 2026 revenue growth to $26.6B. Key risks include oil price volatility and high capital expenditures, but strong institutional ownership and zero sell ratings underscore confidence in its disciplined capital allocation and operational execution.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
